Figure 6
Figure 6. EFS is better predicted by NK alloreactivity than by the missing ligand model. (A) The missing ligand model breaks the non-NK alloreactive EFS curve, shown in Figure 5A, into 2 curves according to whether donors possessed an extra KIR(s) for which neither donor nor recipient had HLA ligand(s), ie, missing ligand, versus no missing ligand. The 2 curves do not differ significantly. (B) In the missing ligand model our NK alloreactive transplants (KIR ligand mismatched) are combined with the missing ligand transplants and compared with the no missing ligand transplants. No significant difference emerged (P = .28). EFS in the missing ligand cohort was worse than after transplantation from NK alloreactive donors (B versus Figure 4).

EFS is better predicted by NK alloreactivity than by the missing ligand model. (A) The missing ligand model breaks the non-NK alloreactive EFS curve, shown in Figure 5A, into 2 curves according to whether donors possessed an extra KIR(s) for which neither donor nor recipient had HLA ligand(s), ie, missing ligand, versus no missing ligand. The 2 curves do not differ significantly. (B) In the missing ligand model our NK alloreactive transplants (KIR ligand mismatched) are combined with the missing ligand transplants and compared with the no missing ligand transplants. No significant difference emerged (P = .28). EFS in the missing ligand cohort was worse than after transplantation from NK alloreactive donors (B versus Figure 4).

Close Modal

or Create an Account

Close Modal
Close Modal